- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07690657
Evaluating Intervention Allocation Policies for Reducing Hospital Readmissions at Michigan Medicine
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The intervention affects only how the TOC bundle is assigned and does not alter how the telephone calls are delivered. For example, both care navigators and pharmacists receive the same patient information and follow the same call procedures before and after the intervention.
Individuals with predicted benefits greater than the 40% quantile are assigned the phone call bundle while others were not assigned the bundle. During the trial the 40% quantile will be dynamically determined using discharge data from the previous week.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Stephanie Shepard, PhD
- Telefonnummer: 734-647-1098
- E-mail: sdokeefe@umich.edu
Studiesteder
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- The University of Michigan
-
Kontakt:
- Stephanie Shepard, PhD
- Telefonnummer: 734-647-1098
- E-mail: sdokeefe@umich.edu
-
Ledende efterforsker:
- Jenna Wiens, PhD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Patient meets the primary care established rule at Michigan Medicine (MM), AND
- Patient's primary care physician (PCP) Department is one of our General Medicine or Family Medicine or Medical-Pediatrics departments, AND
- Inpatient class is Inpatient or Observation or Obs Greater than 48 hours or Outpatient in a Bed or Extended Recovery or Hospital Care at Home Inpatient or Hospital Care at Home Observation, AND
- Discharged from General Medicine or Family Medicine or Medicine Observation services, AND
- Disposition of home or home with home care
Exclusion Criteria:
- Physician Organization of Michigan Accountable Care Organization (POM ACO)
- Sepsis patients (had a diagnosis of sepsis during admission, active or resolved on the hospital problem list)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Control Arm/Standard of care
The Control Arm, in which patients with a LACE Index score of 9 or greater on the day of hospital discharge will receive TOC interventions.
This is the currently implemented allocation policy at Michigan Medicine.
In this setting, approximately 60% of patients receive the TOC intervention.
Thus, we will use a threshold of the 40th percentile for assigning the TOC telephone call bundle.
Note that to maintain the 60% intervention rate throughout the study, the score threshold (LACE 9 or greater) will be monitored and dynamically adjusted.
The LACE Index has four components: Length of Stay (L), Acuity of the Admission (A), Comorbidities (C), and Emergency Department Visits (E), and estimates the risk of a patient having an unplanned hospital readmission after being discharged from their current encounter.
|
The LACE Index has four components: Length of Stay (L), Acuity of the Admission (A), Comorbidities (C), and Emergency Department Visits (E), and estimates the risk of a patient having an unplanned hospital readmission after being discharged from their current encounter.
|
|
Eksperimentel: Experimental Arm
The Experimental Arm, in which Causal-Hospital reAdmission Risk Prediction Model (C-HARP) scores will be used to allocate TOC interventions.
C-HARP is a machine learning model that leverages routinely collected and stored patient data in the electronic health record (EHR) to estimate how much a patient will benefit from receiving MM's TOC telephone call bundle.
The assignment threshold will be defined as the 40th percentile of C-HARP scores within the most recent 100 days of the target cohort, so that approximately 60% of patients are assigned the telephone call bundle.
Based on current retrospective data, this threshold corresponds to a C-HARP score of 18.
|
The Experimental Arm will allocate TOC interventions based on scores generated by the Causal-Hospital reAdmission Risk Prediction Model (C-HARP), C-HARP is a linear model that leverages routinely collected and stored patient data in the electronic health record (EHR) to estimate how much a patient will benefit from receiving Michigan Medicine's (MM's) TOC telephone call bundle.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The number of 30-day all-cause unplanned readmission or death
Tidsramme: 30 calendar days following the index discharge
|
An unplanned readmission is defined as any not canceled inpatient, outpatient, or observation hospital admission with an admission type not recorded as "scheduled."
Deaths are determined using the Michigan Death Index and matched to patient records using Social Security numbers.
|
30 calendar days following the index discharge
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The number of 90-day all-cause unplanned readmission or death
Tidsramme: 90 calendar days following the index discharge
|
An unplanned readmission is defined as any not canceled inpatient, outpatient, or observation hospital admission with an admission type not recorded as "scheduled."
Deaths are determined using the Michigan Death Index and matched to patient records using Social Security numbers.
|
90 calendar days following the index discharge
|
|
Time to first 90-day all-cause unplanned readmission or death
Tidsramme: 90 calendar days following the index discharge
|
An unplanned readmission is defined as any not canceled inpatient, outpatient, or observation hospital admission with an admission type not recorded as "scheduled."
Deaths are determined using the Michigan Death Index and matched to patient records using Social Security numbers.
|
90 calendar days following the index discharge
|
|
TOC telephone call bundle completion (care navigator call)
Tidsramme: 5 calendar days after discharge.
|
A care navigator call is considered complete if a completed call record is observed within 5 calendar days after discharge. Calls are considered incomplete if the corresponding completed call record occurs after an all-cause unplanned readmission. |
5 calendar days after discharge.
|
|
TOC telephone call bundle completion (clinical pharmacist call)
Tidsramme: 14 calendar days after discharge
|
A clinical pharmacist call is considered complete if a completed call record is observed within 14 calendar days after discharge. Calls are considered incomplete if the corresponding completed call record occurs after an all-cause unplanned readmission. |
14 calendar days after discharge
|
|
TOC telephone call bundle completion (both calls)
Tidsramme: 14 calendar days after discharge
|
Completed the care navigator call and completed the clinical pharmacist call. Calls are considered incomplete if the corresponding completed call record occurs after an all-cause unplanned readmission. |
14 calendar days after discharge
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studiestol: Jenna Wiens, PhD, University of Michigan
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- HUM00282075
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Overgang af omsorg
-
Xuzhou Medical UniversityIkke rekrutterer endnuIkke-invasiv CAR-T-celleovervågning | BCMA-målrettet PET-skanning | CAR-T-cellebiodistribution og -persistens | GMP-overensstemmende Radiopharmaka-præparation
-
The Affiliated Hospital of Xuzhou Medical UniversityRekrutteringCLL | SLL | CAR-T celleterapiKina
-
Duke UniversityNational Institutes of Health (NIH)RekrutteringHæmatopoietisk stamcelletransplantation | CAR-T celleterapiForenede Stater
-
Patrick C. Johnson, MDRekruttering
-
Stiftung Swiss Tumor InstituteKlinik Hirslanden, Zurich; Palleos Healthcare GmbHRekrutteringPatientrapporterede resultatmål | CAR T-celleterapiSchweiz
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRekrutteringCAR-T Terapi KomplikationerItalien
-
University Health Network, TorontoRekrutteringLymfom, der modtager CAR-T-terapiCanada
-
The Lymphoma Academic Research OrganisationBristol-Myers Squibb; Novartis; Gilead SciencesRekrutteringHæmatopatologi kvalificeret eller CAR-t-cellebehandlingFrankrig
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...University of MilanAfsluttet300 studerende ved University of Milan School of MedicineItalien
-
Henan Cancer HospitalFundamenta Therapeutics, Ltd.Ikke rekrutterer endnuAllogen, CAR-T, proteinsekvestrering, ikke-genredigeretKina
Kliniske forsøg med The LACE Index TOC assignment
-
Hospices Civils de LyonAfsluttetAmbulant pleje | Beredskab, Sygehus | Sundhedstjenester for ældreFrankrig
-
Gaziosmanpasa Research and Education HospitalIkke rekrutterer endnuSlidgigt | Rheumatoid arthritis
-
Assiut UniversityAfsluttetInflammatoriske tarmsygdomme | Seksuelle funktionsforstyrrelserEgypten
-
Medical University of LublinAfsluttet
-
Sanjay Gupta PhDAfsluttetFase I prostatakræft | Stadie IIA prostatakræft | Stadie IIB prostatakræftForenede Stater
-
Tampere UniversityTurku University Hospital; Helsinki University Central Hospital; Oulu University... og andre samarbejdspartnereAktiv, ikke rekrutterendeDupuytren KontrakturFinland